

THE ANTIMICROBIAL ADVOCATE

NE ASAP
NEWSLETTER

Volume 3: Issue 8
August 2026

In this Issue

Thank you! - Page 1

2025 Nebraska State
Antibiogram Report - Page 2

Outpatient antibiotic
durations - Page 3

2026 IDSA Guidance on
Drug-Resistant Gram-
Negative Infections - Page 4

Thank you

Thank you to all of the attendees and planners
that helped to make the **2026 Nebraska
Infectious Diseases Conference** a success!



With over 325 registered
attendees, this was the largest
conference to date!

2025 Nebraska State Antibioqram Report



[Link to the Report](#)

The 2025 Nebraska State Antibioqram Report is available now on the DHHS Healthcare Associated Infections and Antimicrobial Resistance website!

The report includes:

Statewide and Local Health Department Antibioqrams

Antibiotic Susceptibility Heat Maps of Significant Drug-Bug Combinations

Trends in Antibiotic Susceptibility in Nebraska, 2020-2025

Supplemental Data

NEBRASKA DHHS HEALTHCARE-ASSOCIATED INFECTIONS AND ANTIMICROBIAL RESISTANCE PROGRAM

NEBRASKA STATE ANTIBIOGRAM REPORT 2025



Prepared By:

Jenna Preusker, PharmD, BCPS, BCIDP
Juan Teran Plasencia, MD
Kanishka, MPH
Frida Salgado, MS, MPH
M. Salman Ashraf, MBBS

Published August 2026

NEBRASKA
Good Life. Great Mission.
DEPT. OF HEALTH AND HUMAN SERVICES

Shorter is Better:

Decreasing Durations for Common Outpatient Antibiotic Prescriptions

Helpful Links:

[UNMC Ambulatory AS Protocols](#)

[UNMC Durations of Therapy](#)



255.9 Million

Ambulatory antibiotic prescriptions were written in 2024 (CDC)




15%

Estimated to be for too long of a duration



76.77 Million

Antibiotic days could be saved if 15% were shortened by 2 days




Bacterial Sinusitis

5 days



Community acquired pneumonia

3-5 days



UTI

3-5 days



Cellulitis

5 days

Avoid defaulting to 7-10 day courses when shorter therapy is appropriate!

2026 IDSA Guidance on Drug-Resistant Gram-Negative Infections

On July 30, 2026, the Infectious Diseases Society of America published a 2026 update to its 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections.



[Link to the Guidance](#)

This updated guidance reflects changes to the management of:

**Enterobacterales
(ESBL or AmpC-
producing and
carbapenem-
resistant
organisms)**

***Pseudomonas
aeruginosa*
with difficult-
to-treat
resistance**

**Carbapenem-
resistant
*Acinetobacter
baumannii***

***Stenotrophomonas
maltophilia***

In addition, an updated Table 1 contains antibiotic dosing suggestions that reflect the most current available evidence and an updated Table 2 contains 2026 CLSI antibiotic susceptibility breakpoint data.

